FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma (RCC) progression. Preclinical evidence suggests that baseline elevated tumor glucose metabolism as quantified by FDG-PET ([18F]...

Full description

Bibliographic Details
Main Authors: Chen, James L, Appelbaum, Daniel E, Kocherginsky, Masha, Cowey, Charles L, Kimryn Rathmell, Wendy, McDermott, David F, Stadler, Walter M
Format: Online
Language:English
Published: Blackwell Science Inc 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799289/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799289/

Similar Items